The global biosurgery market was valued at USD 15.85 billion in 2025, the base year of the study. Polaris Market Research projects the market to reach USD 16.85 billion in 2026 and USD 27.66 billion by 2034, growing at a CAGR of 6.38% during the forecast period 2026–2034. North America was the largest regional market in 2025 with a 40.4% revenue share. Key players include Artivion, Inc.; Aroa Biosurgery; B. Braun SE; Baxter; BD; INTEGRA LIFESCIENCES; Johnson & Johnson Services, Inc.; Medtronic; Pfizer Inc.; Sanofi; and Stryker.

What Biosurgery Delivers to Surgical Teams

Biosurgery uses living organisms or biologically compatible materials to treat disease, repair tissue, and promote healing. Compared with conventional suturing and stapling, biosurgery products improve tissue sealing and bleeding control and minimize surgical trauma. These advantages translate into faster patient recovery, lower infection risks, and shorter hospital stays, and they make the approach highly compatible with minimally invasive procedures across cardiovascular, orthopedic, neurological, and general operations. The technique also encompasses natural glues for sealing wounds and biotherapeutic approaches such as gene and cellular therapies in orthopedics, urology, and neurosurgery.

Surgical Sealants Lead the Product Mix

Surgical sealants accounted for a 23.8% revenue share in 2025. Their use spans cardiovascular, pulmonary, and hepatic procedures, where they prevent leakage of air, blood, and other bodily fluids, improving outcomes and minimizing postoperative complications. Hospitals aiming to reduce operative time and enhance healing have increased demand, while synthetic and natural sealants with improved elasticity, strength, and biocompatibility have widened adoption. A rising volume of elective and complex surgeries, particularly among older populations, continues to propel the segment.

Hemostatic Agents and Tissue Adhesives Advance

Hemostatic agents are one of six product segments in the biosurgery market. Innovations such as next-generation tissue adhesives, smart hemostats, and bioactive scaffolds are enhancing surgical precision, reducing complications, and making biosurgery more appealing to surgeons and hospitals. Baxter and BD focus on innovation in fibrin sealants and surgical hemostats, leveraging strong R&D capabilities to address complex surgical needs, while hemostats, tissue adhesives, and mesh grafts play a critical role in geriatric procedures.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/biosurgery-market

General Surgery Dominates; Cardiovascular Accelerates

General surgery held a 35.0% revenue share in 2025 because abdominal, gastrointestinal, and hepatobiliary procedures require effective bleeding control and tissue sealing. Rising volumes of hernia repairs, appendectomies, and colorectal surgeries, along with lifestyle-related disorders such as obesity and gastrointestinal diseases, increase demand. Cardiovascular surgery is projected to grow at the highest application CAGR of 6.40%, driven by increasing heart disease and a rising number of open-heart and vascular procedures. Surgeons rely on specialized biosurgical products for rapid hemostasis in high-risk heart operations, and growing hypertension and diabetes support demand for bypass grafts, valve replacements, and aortic repairs.

Biosurgery Market Demand Drivers and Regional View

The World Health Organization reported at least 43 million deaths from noncommunicable diseases in 2021, and chronic conditions often lead to complications that necessitate biosurgical products. Rising advancement in biosurgical products and a growing volume of general, cardiovascular, orthopedic, and plastic surgeries are expected to create lucrative opportunities during the forecast period, and Medtronic dominates with extensive product lines including advanced hemostatic agents and sealants. Government support is also rising: according to the Economic Survey, the share of government health expenditure in India's total health expenditure increased from 29.0% to 48.0% between FY15 and FY22. In North America, the US held an 81.8% regional share in 2025, helped by high healthcare spending and a focus on minimally invasive procedures. Asia Pacific is projected to register a 7.47% CAGR from 2026 to 2034. The high cost of biosurgery products and procedures, however, limits adoption in emerging regions and among patients without adequate insurance.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market